- Home
- / Spexis
Spexis
Stock Price
CHF0.1
2024-10-29
Market Capitalization
CHF6.4 M
2024-10-29
Spexis Summary
Company Summary
- Overview
- Spexis (formerly known as Polyphor) is a bioengineering company that specializes in respiratory therapeutics. It offers rare disease and oncology treatments.
- Type
- Public
- Status
- Active
- Founded
- 1996
- HQ
- Allschwil, CH | view all locations
- Website
- https://spexisbio.com
- Cybersecurity rating
Table of Contents
Key People
Stephan Wehselau, Chief Operating Officer
Dennis Ausiello, Vice Chairman
Juergen Froehlich, Chief Medical Officer
LocationsView all
1 location detected
Allschwil, BL HQ
Switzerland
Hegenheimermattweg 125
Spexis Financials
Summary Financials
- Gross profit (FY, 2023)
- CHF755.0K
- Net income (FY, 2023)
- (CHF19.6M)
- Cash (FY, 2023)
- CHF511.0K
- EBIT (FY, 2023)
- (CHF20.6M)
- Enterprise value
- $14.2M